Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01496053
Recruitment Status : Unknown
Verified December 2011 by Oslo University Hospital.
Recruitment status was:  Recruiting
First Posted : December 21, 2011
Last Update Posted : April 14, 2015
ImmunoPharma AS
Information provided by (Responsible Party):
Oslo University Hospital

Brief Summary:

Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with ulcerative colitis (UC) and Crohn`s disease (CD), experience clinical, biochemical and genetical improvement in their disease.

A prospective randomised study comparing the mushroom extract with placebo.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Crohn's Disease Inflammatory Bowel Disease Dietary Supplement: AndoSan Dietary Supplement: Sugar Extract Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study
Study Start Date : December 2011
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: AndoSan
AndoSan given to IBD patients
Dietary Supplement: AndoSan
AndoSan 30 ml x 2 for 21 days

Sham Comparator: Sugar extract
Sugar extract to IBD patients
Dietary Supplement: Sugar Extract
Sham comparator

Primary Outcome Measures :
  1. Reduction in biochemical blood parameters (pro-inflammatory cytokines) [ Time Frame: 21 days ]

Secondary Outcome Measures :
  1. Reduction of calprotectin in feces. [ Time Frame: 21 days ]
  2. Clinical symptom score. [ Time Frame: 21 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • moderate disease

Exclusion Criteria:

  • serious disease,
  • biological treatment,
  • pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01496053

Contact: Egil Johnson, MD. Phd 0047 47416334
Contact: Dag T Forland, MD. Phd 0047 90905384

Oslo University Hospital, Ulleval Recruiting
Oslo, Norway, 0407
Contact: Egil Johnson, MD. Phd    0047 47416334   
Sponsors and Collaborators
Oslo University Hospital
ImmunoPharma AS
Principal Investigator: Egil Johnson, MD. Phd Ullevaal University Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Oslo University Hospital Identifier: NCT01496053     History of Changes
Other Study ID Numbers: AbM2012-IBD
First Posted: December 21, 2011    Key Record Dates
Last Update Posted: April 14, 2015
Last Verified: December 2011

Keywords provided by Oslo University Hospital:
Cytokine levels in blood
Calprotectin in feces
Clinical symptom score.

Additional relevant MeSH terms:
Crohn Disease
Colitis, Ulcerative
Intestinal Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Anti-Inflammatory Agents